- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00787969
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVES:
I. To assess the efficacy and safety of the combination of rituximab, cladribine, and temsirolimus for newly diagnosed mantle cell lymphoma.
II. To determine the maximum tolerated dose (MTD) of temsirolimus combined with a fixed dose and schedule of rituximab and cladribine. (Phase I) III. To assess the efficacy of the combination of rituximab, cladribine, and temsirolimus for newly diagnosed mantle cell lymphoma with the proportion of complete responses as the primary endpoint. (Phase II)
SECONDARY OBJECTIVES:
I. To assess other measures of efficacy of the regimen including progression free survival, duration of response, and overall survival.
II. To assess the toxicity profile of the combination of rituximab, cladribine, and temsirolimus.
III. To assess efficacy using traditional lymphoma parameters and absolute lymphocyte count.
IV. To assess metabolic markers (hyperglycemia, hyperlipidemia) as markers of mammalian target of rapamycin (mTOR) inhibition using the glucose and lipid measurements being performed in the clinical laboratory as part of routine care.
V. To correlate response with serum free light chains, single nucleotide polymorphisms (SNPs) in host immune genes, vitamin D metabolites, and phosphatidylinositide 3-kinase (PI3K) pathway member expression.
VI. As part of ongoing research for North Central Cancer Treatment Group (NCCTG) lymphoma studies, paraffin-embedded tissue blocks/slides and blood products will be banked for future studies.
OUTLINE: This is a phase I, dose-escalation study of temsirolimus followed by a phase II study.
Patients receive rituximab intravenously (IV) on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim subcutaneously (SC) on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 4 months for 3 years.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85259-5499
- Mayo Clinic Scottsdale
-
-
Illinois
-
Bloomington, Illinois, Estados Unidos, 61701
- Illinois CancerCare - Bloomington
-
Bloomington, Illinois, Estados Unidos, 61701
- St. Joseph Medical Center
-
Canton, Illinois, Estados Unidos, 61520
- Illinois CancerCare - Canton
-
Canton, Illinois, Estados Unidos, 61520
- Graham Hospital
-
Carthage, Illinois, Estados Unidos, 62321
- Memorial Hospital
-
Carthage, Illinois, Estados Unidos, 62321
- Illinois CancerCare - Carthage
-
Eureka, Illinois, Estados Unidos, 61530
- Illinois CancerCare - Eureka
-
Eureka, Illinois, Estados Unidos, 61530
- Eureka Community Hospital
-
Galesburg, Illinois, Estados Unidos, 61401
- Illinois CancerCare - Galesburg
-
Galesburg, Illinois, Estados Unidos, 61401
- Galesburg Clinic, PC
-
Havana, Illinois, Estados Unidos, 62644
- Mason District Hospital
-
Havana, Illinois, Estados Unidos, 62644
- Illinois CancerCare - Havana
-
Kewanee, Illinois, Estados Unidos, 61443
- Illinois CancerCare - Kewanee Clinic
-
Macomb, Illinois, Estados Unidos, 61455
- Illinois CancerCare - Macomb
-
Macomb, Illinois, Estados Unidos, 61455
- Mcdonough District Hospital
-
Monmouth, Illinois, Estados Unidos, 61462
- Illinois CancerCare - Monmouth
-
Monmouth, Illinois, Estados Unidos, 61462
- OSF Holy Family Medical Center
-
Normal, Illinois, Estados Unidos, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, Estados Unidos, 61761
- Community Cancer Center
-
Normal, Illinois, Estados Unidos, 61761
- Illinois CancerCare - Community Cancer Center
-
Ottawa, Illinois, Estados Unidos, 61350
- Community Hospital of Ottawa
-
Ottawa, Illinois, Estados Unidos, 61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin, Illinois, Estados Unidos, 61554
- Cancer Treatment Center at Pekin Hospital
-
Pekin, Illinois, Estados Unidos, 61603
- Illinois CancerCare - Pekin
-
Peoria, Illinois, Estados Unidos, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Estados Unidos, 61614
- Proctor Hospital
-
Peoria, Illinois, Estados Unidos, 61637
- OSF St. Francis Medical Center
-
Peoria, Illinois, Estados Unidos, 61615
- CCOP - Illinois Oncology Research Association
-
Peoria, Illinois, Estados Unidos, 61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peru, Illinois, Estados Unidos, 61354
- Illinois CancerCare - Peru
-
Peru, Illinois, Estados Unidos, 61354
- Illinois Valley Community Hospital
-
Princeton, Illinois, Estados Unidos, 61356
- Perry Memorial Hospital
-
Princeton, Illinois, Estados Unidos, 61356
- Illinois CancerCare - Princeton
-
Spring Valley, Illinois, Estados Unidos, 61362
- Illinois CancerCare - Spring Valley
-
-
Indiana
-
Elkhart, Indiana, Estados Unidos, 46515
- Elkhart General Hospital
-
Elkhart, Indiana, Estados Unidos, 46514-2098
- Elkhart Clinic, LLC
-
Elkhart, Indiana, Estados Unidos, 46514
- Michiana Hematology-Oncology, PC - Elkhart
-
Kokomo, Indiana, Estados Unidos, 46904
- Howard Community Hospital
-
La Porte, Indiana, Estados Unidos, 46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
Mishawaka, Indiana, Estados Unidos, 46545-1470
- Michiana Hematology-Oncology, PC - South Bend
-
Mishawaka, Indiana, Estados Unidos, 46545-1470
- Saint Joseph Regional Medical Center
-
Plymouth, Indiana, Estados Unidos, 46563
- Michiana Hematology Oncology PC - Plymouth
-
South Bend, Indiana, Estados Unidos, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, Estados Unidos, 46601
- CCOP - Northern Indiana CR Consortium
-
Westville, Indiana, Estados Unidos, 46391
- Michiana Hematology Oncology PC - La Porte
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- McFarland Clinic, PC
-
Cedar Rapids, Iowa, Estados Unidos, 52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids, Iowa, Estados Unidos, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Clive, Iowa, Estados Unidos, 50325
- Medical Oncology and Hematology Associates - West Des Moines
-
Des Moines, Iowa, Estados Unidos, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, Estados Unidos, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, Estados Unidos, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, Estados Unidos, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, Estados Unidos, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Estados Unidos, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Mason City, Iowa, Estados Unidos, 50401
- Mercy Cancer Center at Mercy Medical Center - North Iowa
-
Sioux City, Iowa, Estados Unidos, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, Estados Unidos, 51102
- Mercy Medical Center - Sioux City
-
Sioux City, Iowa, Estados Unidos, 51104
- St. Luke's Regional Medical Center
-
-
Kansas
-
Chanute, Kansas, Estados Unidos, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, Estados Unidos, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, Estados Unidos, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott, Kansas, Estados Unidos, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Estados Unidos, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Estados Unidos, 67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence, Kansas, Estados Unidos, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Estados Unidos, 67901
- Cancer Center of Kansas, PA - Liberal
-
Newton, Kansas, Estados Unidos, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, Estados Unidos, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, Estados Unidos, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, Estados Unidos, 67401
- Cancer Center of Kansas, PA - Salina
-
Wellington, Kansas, Estados Unidos, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, Estados Unidos, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, Estados Unidos, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, Estados Unidos, 67214
- CCOP - Wichita
-
Wichita, Kansas, Estados Unidos, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, Estados Unidos, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, Estados Unidos, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Michigan
-
Battle Creek, Michigan, Estados Unidos, 49017
- Battle Creek Health System Cancer Care Center
-
Big Rapids, Michigan, Estados Unidos, 49307
- Mecosta County Medical Center
-
Escanaba, Michigan, Estados Unidos, 49431
- Green Bay Oncology, Limited - Escanaba
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, Estados Unidos, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Iron Mountain, Michigan, Estados Unidos, 49801
- Dickinson County Healthcare System
-
Muskegon, Michigan, Estados Unidos, 49443
- Mercy General Health Partners
-
Niles, Michigan, Estados Unidos, 49120
- Michiana Hematology Oncology PC - Niles
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Lakeside Cancer Specialists, PLLC
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Lakeland Regional Cancer Care Center - St. Joseph
-
Traverse City, Michigan, Estados Unidos, 49684
- Munson Medical Center
-
Wyoming, Michigan, Estados Unidos, 49519
- Metro Health Hospital
-
-
Minnesota
-
Burnsville, Minnesota, Estados Unidos, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Estados Unidos, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth, Minnesota, Estados Unidos, 55805
- CCOP - Duluth
-
Duluth, Minnesota, Estados Unidos, 55805-1983
- Duluth Clinic Cancer Center - Duluth
-
Duluth, Minnesota, Estados Unidos, 55805
- Miller - Dwan Medical Center
-
Edina, Minnesota, Estados Unidos, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Estados Unidos, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, Estados Unidos, 55350
- Hutchinson Area Health Care
-
Maplewood, Minnesota, Estados Unidos, 55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood, Minnesota, Estados Unidos, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, Estados Unidos, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, Estados Unidos, 55422-2900
- Humphrey Cancer Center at North Memorial Outpatient Center
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic Cancer Center
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, Estados Unidos, 55102
- United Hospital
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Regions Hospital Cancer Care Center
-
Shakopee, Minnesota, Estados Unidos, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
Stillwater, Minnesota, Estados Unidos, 55082
- Lakeview Hospital
-
Waconia, Minnesota, Estados Unidos, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Estados Unidos, 56201
- Willmar Cancer Center at Rice Memorial Hospital
-
Woodbury, Minnesota, Estados Unidos, 55125
- Minnesota Oncology Hematology, PA - Woodbury
-
-
Montana
-
Billings, Montana, Estados Unidos, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, Estados Unidos, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, Estados Unidos, 59107-7000
- Billings Clinic - Downtown
-
Billings, Montana, Estados Unidos, 59102
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Deaconess Cancer Center
-
Butte, Montana, Estados Unidos, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, Estados Unidos, 59405
- Great Falls Clinic - Main Facility
-
Great Falls, Montana, Estados Unidos, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
Havre, Montana, Estados Unidos, 59501
- Northern Montana Hospital
-
Helena, Montana, Estados Unidos, 59601
- St. Peter's Hospital
-
Kalispell, Montana, Estados Unidos, 59901
- Kalispell Regional Medical Center
-
Kalispell, Montana, Estados Unidos, 59901
- Glacier Oncology, PLLC
-
Kalispell, Montana, Estados Unidos, 59901
- Kalispell Medical Oncology at KRMC
-
Missoula, Montana, Estados Unidos, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
North Dakota
-
Bismarck, North Dakota, Estados Unidos, 58501
- Bismarck Cancer Center
-
Bismarck, North Dakota, Estados Unidos, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, Estados Unidos, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, Estados Unidos, 58502
- St. Alexius Medical Center Cancer Center
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos, 57701
- Rapid City Regional Hospital
-
-
Wisconsin
-
Green Bay, Wisconsin, Estados Unidos, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Estados Unidos, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Estados Unidos, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, Estados Unidos, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
Manitowoc, Wisconsin, Estados Unidos, 54221-1450
- Holy Family Memorial Medical Center Cancer Care Center
-
Marinette, Wisconsin, Estados Unidos, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Oconto Falls, Wisconsin, Estados Unidos, 54154
- Green Bay Oncology, Limited - Oconto Falls
-
Sheboygan, Wisconsin, Estados Unidos, 53081
- St. Nicholas Hospital
-
Sturgeon Bay, Wisconsin, Estados Unidos, 54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
-
Wyoming
-
Sheridan, Wyoming, Estados Unidos, 82801
- Welch Cancer Center at Sheridan Memorial Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically confirmed mantle cell lymphoma (MCL); the diagnosis must be confirmed by NCCTG pre-registration pathology review by Dr. Paul Kurtin or his designate; it is recommended that the biopsy be an excisional biopsy, but adequate core-needle biopsies will be accepted as long as they are considered adequate for registration by Dr. Kurtin or his designate; the tumor must be cyclin D-1 positive by immunohistochemistry or have evidence of a t(11;14) translocation by fluorescence based in situ hybridization (FISH) or cytogenetics
Measurable or assessable disease, defined as at least one of the following:
- A lymph node or tumor mass that is >= 2.0 cm in at least one dimension by positron emission tomography (PET)/computed tomography (CT), CT, magnetic resonance imaging (MRI), or plain radiograph imaging
- Splenic enlargement may be used as a measurable parameter if the spleen is palpable >= 3 cm below the left costal margin
- Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral blood, liver, lungs, or bowel by lymphoma without a discrete mass would constitute assessable, but not measurable, disease
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2, or 3
- Life expectancy >= 12 weeks
- Absolute neutrophil count (ANC) >= 1,500/mm³
- Platelet count (PLT) >= 100,000/mm³
- Serum creatinine =< 2.0 mg/dL
- Serum total bilirubin (or direct bilirubin if total is abnormal) =< institutional upper limit of normal (ULN) with or without secondary liver involvement
- Serum glutamic oxaloacetic transaminase (SGOT) =< 3 x institutional ULN (exception: if there is liver involvement, SGOT must be =< 5 x institutional ULN)
- Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Willingness to return to NCCTG enrolling institution for follow-up
- Willingness to provide the blood specimens as required by the protocol
- Willingness to provide tissue specimens as required by the protocol
- Willing to return to NCCTG enrolling institution for follow-up
- Willing to provide blood and tissue specimens as required by the protocol
- Willing to abstain from eating grapefruit or drinking grapefruit juice
- Willingness to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study
Exclusion Criteria
- Any prior therapy for mantle cell non-Hodgkin lymphoma including radiation therapy; exception: patient may have undergone a splenectomy for diagnosis, cytopenia, or systematic splenomegaly
- Active or uncontrolled infection
Any of the following cardiac conditions:
- Uncontrolled high blood pressure
- Unstable angina
- Active congestive heart failure
- Myocardial infarction =< 6 months
- Serious uncontrolled cardiac arrhythmia
- Known central nervous system (CNS) involvement
Any of the following:
- Pregnant women or women of reproductive ability who are unwilling to use effective contraception while taking the drug and for 12 months after stopping treatment
- Nursing women
- Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 12 months after stopping treatment
- Medical or psychiatric conditions which, in the opinion of the investigator, make the patient a poor risk for participation
- Known to be human immunodeficiency virus (HIV) positive; HIV testing is not required but should be done if clinically indicated; HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study
- Concurrent malignancy =< 5 years ago; exceptions: carcinoma in situ of the cervix, resected basal cell or squamous cell carcinomas of the skin, or prostate cancer that is in remission following a radical retropubic prostatectomy or radiation therapy; if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
- Known hypersensitivity to rituximab or its components, or to murine proteins
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
- Prior treatment with an mTOR inhibitor
- Autologous or allogeneic stem cell transplant planned as part of initial therapy
- Receiving enzyme-inducing antiepileptic drugs (enzyme inducing anti-epileptic drugs [EIAEDs]; e.g., phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, phenobarbital, or primidone); any other potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer such as rifampin, glucocorticoids at greater than adrenal replacement levels, or St. John's wort; or receiving strong CYP3A4 inhibitors * Note: if these agents are discontinued, temsirolimus therapy can begin >= 7 days after discontinuation of such agent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment (rituximab, cladribine, temsirolimus)
Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5.
Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6.
Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
Give IV
Give IV
Give IV
Give SC
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Number of dose limiting toxicity incidents as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 3.0 (Phase I)
Periodo de tiempo: 28 days
|
28 days
|
|
Proportion of complete tumor responses defined as complete remission (CR) as the objective status (Phase II)
Periodo de tiempo: Up to 5 years
|
Up to 5 years
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Sobrevivencia promedio
Periodo de tiempo: hasta 5 años
|
hasta 5 años
|
|
Tiempo de supervivencia
Periodo de tiempo: Hasta 5 años
|
Hasta 5 años
|
|
Progression-free survival (PFS)
Periodo de tiempo: up to 5 years
|
up to 5 years
|
|
Time to disease progression
Periodo de tiempo: up to 5 years
|
up to 5 years
|
|
Duration of response, defined as date at which the patient's objective status is first noted to be either a CR or partial remission to the date progression is documented
Periodo de tiempo: Up to 5 years
|
Up to 5 years
|
|
Frequency and severity of adverse events assessed by CTCAE v3.0
Periodo de tiempo: Up to 5 years
|
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: David J. Inwards, MD, Mayo Clinic
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Neoplasias
- Trastornos linfoproliferativos
- Enfermedades linfáticas
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma
- Linfoma De Células Del Manto
- Efectos fisiológicos de las drogas
- Agentes antiinfecciosos
- Agentes antirreumáticos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes antineoplásicos inmunológicos
- Agentes antibacterianos
- Antibióticos, Antineoplásicos
- Agentes antifúngicos
- Rituximab
- Sirolimus
- Cladribina
Otros números de identificación del estudio
- NCCTG-N078D
- NCI-2009-00669 (Identificador de registro: CTRP (Clinical Trials Reporting System))
- CDR0000619329 (Identificador de registro: PDQ (Physician Data Query))
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .